NVO Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 62.44% beat DBV Technologies SA's return on equity of -280.59%.

Novo Nordisk A/S has a consensus price target of $53.61, signalling upside risk potential of 36.09%. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 89.16%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk A/S, analysts believe DBV Technologies SA is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.667, which suggesting that the stock is 33.292% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 4.36%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 38.07% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk A/S's net income of $4.2B is higher than DBV Technologies SA's net income of -$33M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.43x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.77x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 62.44% beat Evaxion AS's return on equity of --.

Novo Nordisk A/S has a consensus price target of $53.61, signalling upside risk potential of 36.09%. On the other hand Evaxion AS has an analysts' consensus of $11.75 which suggests that it could grow by 262.65%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.667, which suggesting that the stock is 33.292% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 4.36%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 38.07% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Evaxion AS quarterly revenues of $37.5K. Novo Nordisk A/S's net income of $4.2B is higher than Evaxion AS's net income of -$4.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.43x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.77x versus 2.17x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of 21.74%. Novo Nordisk A/S's return on equity of 62.44% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Novo Nordisk A/S has a consensus price target of $53.61, signalling upside risk potential of 36.09%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 10.54%. Given that Novo Nordisk A/S has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Novo Nordisk A/S is more attractive than Regeneron Pharmaceuticals, Inc..

Novo Nordisk A/S has a beta of 0.667, which suggesting that the stock is 33.292% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 4.36%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Novo Nordisk A/S pays 38.07% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Novo Nordisk A/S's net income of $4.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.43x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.77x versus 5.96x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 33.98% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 62.44% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

Novo Nordisk A/S has a consensus price target of $53.61, signalling upside risk potential of 36.09%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 169.07%. Given that Viking Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Viking Therapeutics, Inc. is more attractive than Novo Nordisk A/S.

Novo Nordisk A/S has a beta of 0.667, which suggesting that the stock is 33.292% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.489%.

Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 4.36%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 38.07% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk A/S quarterly revenues are $12.3B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Novo Nordisk A/S's net income of $4.2B is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 11.43x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 3.77x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.